{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:09:28Z","timestamp":1772183368038,"version":"3.50.1"},"reference-count":45,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Multiple sclerosis (MS) typically presents in young adulthood. Recent data show the highest prevalence of MS in people aged 55 to 64 years; however, there are limited studies of this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Administrative US claims data from IBM-Truven MarketScan commercial and Medicare databases (2011\u20132017) were analyzed. People with MS 50 years or older were assigned to the aging MS cohort (n = 10,746). The matched controls were people 50 years or older without MS (n = 10,746). Multivariable models compared outcomes between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Infections were more frequent in the aging MS cohort vs matched controls (61% vs 45%; P &amp;lt; .0001); urinary tract, acute upper respiratory tract, and herpes zoster were the most frequent infection types. Malignancy rates were 20% for both groups (P = .8167); skin, breast, and prostate malignancies were the most frequent types. Skilled nursing facilities (aging MS cohort, 12%; matched controls, 3%; P &amp;lt; .0001) and MRI (aging MS cohort, 87%; matched controls, 37%; P &amp;lt; .0001) were used more frequently in the aging MS cohort; brain and spine were the most frequent types of MRI in the aging MS cohort. Time to first cane\/walker or wheelchair use was shorter in the aging MS cohort (cane\/walker use: HR, 2.1; 95% CI, 1.9\u20132.3; P &amp;lt; .0001; wheelchair use: HR, 6.9; 95% CI, 6.0\u20138.1; P &amp;lt; .0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In people 50 years or older, measures typically associated with worse health primarily resulted from having MS rather than being a consequence of aging alone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.7224\/1537-2073.2021-124","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T10:01:19Z","timestamp":1663063279000},"page":"56-62","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes and Health Care Service Use in Adults 50 Years or Older With and Without Multiple Sclerosis: A 6-Year Observational Analysis"],"prefix":"10.7224","volume":"25","author":[{"given":"Leorah","family":"Freeman","sequence":"first","affiliation":[{"name":"From the Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA (LF, AL)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashlea","family":"Lucas","sequence":"additional","affiliation":[{"name":"From the Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA (LF, AL)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[{"name":"EMD Serono, Rockland, MA, USA (JZ, BH, TL)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Hayward","sequence":"additional","affiliation":[{"name":"EMD Serono, Rockland, MA, USA (JZ, BH, TL)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallory","family":"Gough","sequence":"additional","affiliation":[{"name":"Ashfield MedComms, an Ashfield Health company, Macclesfield, United Kingdom (MG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrie","family":"Livingston","sequence":"additional","affiliation":[{"name":"EMD Serono, Rockland, MA, USA (JZ, BH, TL)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"issue":"6","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458516634871","article-title":"Aging and multiple sclerosis","volume":"22","author":"Sanai","year":"2016","journal-title":"Mult Scler."},{"issue":"2","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamaneurol.201","article-title":"Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a nationwide population-based cohort study in Sweden","volume":"76","author":"Beiki","year":"2019","journal-title":"JAMA Neurol."},{"issue":"1","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/jnnp-2014-309906","article-title":"A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway","volume":"87","author":"Grytten","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"10","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1007\/s00415-015-7842-0","article-title":"High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991\u20132010)","volume":"262","author":"Kingwell","year":"2015","journal-title":"J Neurol."},{"issue":"16","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1212\/WNL.0000000000005331","article-title":"Temporal trends in multiple sclerosis prevalence and incidence in a large population","volume":"90","author":"Rotstein","year":"2018","journal-title":"Neurology."},{"issue":"10","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."},{"key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"1756286419843450","DOI":"10.1177\/1756286419843450","article-title":"Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age","volume":"12","author":"Briner","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"issue":"1","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol."},{"issue":"8","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"12","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jamda.2013.05.009","article-title":"Proinflammatory cytokines, aging, and age-related diseases","volume":"14","author":"Michaud","year":"2013","journal-title":"J Am Med Dir Assoc."},{"issue":"6","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"e0243150","DOI":"10.1371\/journal.pone.0243150","article-title":"Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis","volume":"16","author":"Johnson","year":"2021","journal-title":"PLoS One."},{"issue":"2","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"101982","DOI":"10.1016\/j.msard.2020.101982","article-title":"Infections in patients diagnosed with multiple sclerosis: a multi-database study","volume":"41","author":"Persson","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"4","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1212\/WNL.0000000000011219","article-title":"Cancer incidence and mortality rates in multiple sclerosis: a matched cohort study","volume":"96","author":"Marrie","year":"2021","journal-title":"Neurology."},{"issue":"13","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"72","author":"Bahmanyar","year":"2009","journal-title":"Neurology."},{"issue":"12","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1177\/1352458519877244","article-title":"Risk of cancer among multiple sclerosis patients, siblings, and population controls: a prospective cohort study","volume":"26","author":"Grytten","year":"2020","journal-title":"Mult Scler."},{"issue":"3","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.msard.2016.07.015","article-title":"Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature","volume":"9","author":"Grebenciucova","year":"2016","journal-title":"Mult Scler Relat Disord."},{"issue":"8","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult Scler."},{"key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.3389\/fimmu.2019.02954","article-title":"Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies","volume":"10","author":"Melamed","year":"2019","journal-title":"Front Immunol."},{"key":"2023031313220466500_","first-page":"214","article-title":"Reducing bias in a propensity score matched-pair sample using greedy matching techniques","author":"Parsons","year":"2001"},{"issue":"11","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care."},{"issue":"5","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult Scler."},{"issue":"1","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1468-1331.2011.03460.x","article-title":"Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age","volume":"19","author":"Lampl","year":"2012","journal-title":"Eur J Neurol."},{"issue":"6","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.4049\/jimmunol.172.6.3437","article-title":"Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly","volume":"172","author":"Deng","year":"2004","journal-title":"J Immunol."},{"issue":"2","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/path.2104","article-title":"Immunosenescence of ageing","volume":"211","author":"Gruver","year":"2007","journal-title":"J Pathol."},{"key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"102420","DOI":"10.1016\/j.msard.2020.102420","article-title":"Infections in patients with multiple sclerosis: a national cohort study in Sweden","volume":"45","author":"Castelo-Branco","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/1744666X.2021.1886924","article-title":"Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment","volume":"17","author":"Otero-Romero","year":"2021","journal-title":"Expert Rev Clin Immunol."},{"issue":"12","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"e0168376","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry","volume":"11","author":"Prosperini","year":"2016","journal-title":"PLoS One."},{"issue":"4","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/joim.13119","article-title":"Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States","volume":"288","author":"Imam","year":"2020","journal-title":"J Intern Med."},{"issue":"5","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"2001112","DOI":"10.1183\/13993003.01112-2020","article-title":"Association between age and clinical characteristics and outcomes of COVID-19","volume":"55","author":"Liu","year":"2020","journal-title":"Eur Respir J."},{"key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"102462","DOI":"10.1016\/j.msard.2020.102462","article-title":"Urinary tract infection in patients with multiple sclerosis: an overview","volume":"46","author":"Medeiros Junior","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement","volume":"27","author":"Moiola","year":"2021","journal-title":"Mult Scler."},{"key":"2023031313220466500_","unstructured":"Zostavax (zoster vaccine live) recommendations. Centers for Disease Control and Prevention.\n\t\t\t\t\tNovember 18, 2020. Accessed March 31, 2021. https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/zostavax\/recommendations.html"},{"key":"2023031313220466500_","unstructured":"Shingrix recommendations. Centers for Disease Control and Prevention.\n\t\t\t\t\tAccessed March 31, 2021. https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/shingrix\/recommendations.html"},{"issue":"24","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1002\/cncr.32632","article-title":"Experts call for greater emphasis on cancer prevention in older adults: since cancer risk increases with age, a fast-growing population of seniors makes preventive efforts more important than ever","volume":"125","author":"Printz","year":"2019","journal-title":"Cancer."},{"issue":"3","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00415-020-10170-5","article-title":"Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study","volume":"268","author":"Zecca","year":"2021","journal-title":"J Neurol."},{"issue":"3","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1352458514564489","article-title":"A systematic review of the incidence and prevalence of cancer in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler."},{"issue":"4","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7224\/1537-2073.2013-046","article-title":"Access to preventive health care in severely disabled women with multiple sclerosis","volume":"17","author":"Dobos","year":"2015","journal-title":"Int J MS Care."},{"issue":"7319","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/bmj.323.7319.968","article-title":"Mobility impairments and use of preventive services in women with multiple sclerosis: observational study","volume":"323","author":"Cheng","year":"2001","journal-title":"BMJ."},{"issue":"2","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7224\/1537-2073-13.2.49","article-title":"Barriers and facilitators to breast cancer screening: a qualitative study of women with multiple sclerosis","volume":"13","author":"Todd","year":"2011","journal-title":"Int J MS Care."},{"issue":"7","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(08)70137-6","article-title":"MRI in multiple sclerosis: current status and future prospects","volume":"7","author":"Bakshi","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"2023031313220466500_","doi-asserted-by":"publisher","first-page":"e0148573","DOI":"10.1371\/journal.pone.0148573","article-title":"Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors","volume":"11","author":"Marck","year":"2016","journal-title":"PLoS One."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/25\/2\/56\/3198879\/i1537-2073-25-2-56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/25\/2\/56\/3198879\/i1537-2073-25-2-56.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:13:13Z","timestamp":1752786793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/outcomes-and-health-care-service-use-in-adults-50-years-or-older-with-and-without-multiple-sclerosis-a-6-year-observational-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2021-124","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}